Dolby Laboratories Inc. (NYSE:DLB) insider Kevin J. Yeaman sold 22,102 shares of the stock in a transaction on Monday, October 10th. The stock was sold at an average price of $55.00, for a total value of $1,215,610.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Kevin J. Yeaman also recently made the following trade(s): On Thursday, August 11th, Kevin J. Yeaman sold 3,287 shares of Dolby Laboratories stock. The stock was sold at an average price of $49.52, for a total value of $162,772.24.
Shares of Dolby Laboratories Inc. (NYSE:DLB) opened at 52.68 on Thursday. Dolby Laboratories Inc. has a 52-week low of $30.38 and a 52-week high of $55.02. The firm has a market cap of $5.40 billion, a price-to-earnings ratio of 25.70 and a beta of 0.57. The firm has a 50-day moving average price of $51.78 and a 200-day moving average price of $48.08.
Dolby Laboratories (NYSE:DLB) last released its quarterly earnings results on Wednesday, July 27th. The company reported $0.76 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.25. Dolby Laboratories had a return on equity of 10.19% and a net margin of 20.19%. The business had revenue of $277.60 million for the quarter, compared to analysts’ expectations of $268.04 million. During the same quarter in the previous year, the firm posted $0.49 earnings per share. The company’s revenue was up 19.8% compared to the same quarter last year. Analysts predict that Dolby Laboratories Inc. will post $1.79 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Algert Global LLC purchased a new stake in shares of Dolby Laboratories during the third quarter valued at about $2,893,000. BNP Paribas Arbitrage SA boosted its stake in shares of Dolby Laboratories by 26.4% in the third quarter. BNP Paribas Arbitrage SA now owns 3,667 shares of the company’s stock valued at $199,000 after buying an additional 766 shares during the last quarter. Macquarie Group Ltd. purchased a new stake in shares of Dolby Laboratories during the second quarter valued at about $2,144,000. Royal Bank of Canada boosted its stake in shares of Dolby Laboratories by 23.8% in the second quarter. Royal Bank of Canada now owns 30,314 shares of the company’s stock valued at $1,450,000 after buying an additional 5,818 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its stake in shares of Dolby Laboratories by 0.5% in the second quarter. Public Employees Retirement System of Ohio now owns 93,859 shares of the company’s stock valued at $4,491,000 after buying an additional 433 shares during the last quarter. Institutional investors and hedge funds own 49.40% of the company’s stock.
Several equities analysts recently issued reports on the company. B. Riley reissued a “neutral” rating and set a $46.00 target price on shares of Dolby Laboratories in a research note on Monday, July 25th. Zacks Investment Research lowered Dolby Laboratories from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 28th. Dougherty & Co increased their target price on Dolby Laboratories from $54.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, July 28th. Finally, JPMorgan Chase & Co. assumed coverage on Dolby Laboratories in a research note on Tuesday, October 4th. They set a “neutral” rating and a $51.00 target price on the stock. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Dolby Laboratories presently has an average rating of “Hold” and a consensus target price of $50.80.
About Dolby Laboratories